Bioatla, INC 8-K filings

BioAtla, Inc. has amended its bylaws, modifying advance notice requirements for stockholder nominations and business proposals.

BioAtla reported its Q4 and full year 2023 financial results, highlighting progress in its clinical programs and upcoming data readouts.

BioAtla, Inc. has awarded cash bonuses and restricted stock units to its executive officers based on the achievement of 2023 clinical, research, and business objectives, and has also approved a 2024 corporate bonus plan.

BioAtla is facing a class action lawsuit challenging certain advance notice bylaw provisions, leading the board to temporarily waive enforcement of those provisions for the upcoming annual meeting.